The University of North Carolina-Chapel HIll (UNC) Clinical Center leads the eight Drug-Induced Liver Injury Network (DILIN) centers in terms of total subject recruitment and number of ancillary studies proposed and conducted. Dr. Paul Watkins has served as chair of the Steering Committee since 2003, when the network was created. Dr. Herbert Bonkovsky was PI at University of Connecticut, one of the original DILIN clinical sites, and since joining the UNC Clinical Center, he has continued to be very active in subject recruitment, ancillary study execution, and general guidance for the network. Dr. Paul Hayashi serves as co-chair of the network's Causality Assessment Committee. In addition to continuing in these administrative roles, we proposed to enroll at least 75 percent of DILIN subjects within 15 days of the initial health care encounter and to continue to lead the network in total subject recruitment (Specific Aim 1). We will work with DILIN investigators to further develop the LiverTox website and to create within it a new DILI diagnostic instrument that is accurate, simple, and practical for clinicians (Specific Aim 2). Finally, we propose conducting DILIN ancillary studies by utilizing fully the research infrastructure and international collaborations we have built specifically for this purpose (Specific Aim 3). With this funding, we believe the UNC Clinical Center would be well positioned to capitalize on the unprecedented resources we would help to develop within DILIN to achieve a level of mechanistic understanding that could revolutionize the diagnosis and management of DILI.
Drug-induced liver injury remains the major adverse event that results in regulatory actions that prevent important new drugs from helping patients. The data and tissue banks created by the DILIN network provide the needed resources to solve this important public health problem.
|Nicoletti, Paola; Aithal, Guruprasad P; Bjornsson, Einar S et al. (2017) Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology 152:1078-1089|
|Church, Rachel J; Watkins, Paul B (2017) The transformation in biomarker detection and management of drug-induced liver injury. Liver Int 37:1582-1590|
|Hayashi, Paul H; Rockey, Don C; Fontana, Robert J et al. (2017) Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology 66:1275-1285|
|Urban, Thomas Jacob; Nicoletti, Paola; Chalasani, Naga et al. (2017) Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B?35:02 as a risk factor. J Hepatol 67:137-144|
|Navarro, Victor J; Khan, Ikhlas; Björnsson, Einar et al. (2017) Liver injury from herbal and dietary supplements. Hepatology 65:363-373|
|Whritenour, Jessica; Ko, Mira; Zong, Qing et al. (2017) Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 14:31-38|
|Russo, Mark W; Steuerwald, Nury; Norton, Harry J et al. (2017) Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int 37:757-764|
|Ahmad, Jawad; Odin, Joseph A; Hayashi, Paul H et al. (2017) Identification and Characterization of Fenofibrate-Induced Liver Injury. Dig Dis Sci 62:3596-3604|
|de Boer, Ynto S; Kosinski, Andrzej S; Urban, Thomas J et al. (2017) Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol 15:103-112.e2|
|Chalasani, Naga; Reddy, K Rajender K; Fontana, Robert J et al. (2017) Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. Am J Gastroenterol 112:1382-1388|
Showing the most recent 10 out of 71 publications